)
Visual
test
Imricor Medical Systems
Imricor Medical Systems (IMR) investor relations material
Imricor Medical Systems Q4 2025 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 TU earnings summary27 Jan, 2026
Executive summary
Achieved multiple world-first procedures in real-time MRI-guided cardiac ablation, including ischemic VT and preclinical in vivo PFA ablations.
Expanded U.S. clinical trial footprint with UVA Health joining the VISABL-AFL trial and additional U.S. hospitals expected to commence procedures in Q1 2026.
Completed major technology integrations with Philips and advanced GE integration for U.S. market entry.
Focused on execution and conversion of a pipeline exceeding 40 sites, with new iCMR lab constructions underway in Saudi Arabia.
Financial highlights
Net cash outflows from operating activities were US$5.2 million in Q4 CY25, up 7% from Q3 CY25; adjusted for a prior grant, up 2% sequentially.
Receipts from customers totaled US$26,000, temporarily impacted by non-revenue-generating clinical trial enrollments.
Payments for operating costs were US$5.4 million, down 2% from the previous quarter.
Cash and short-term investments at 31 December 2025 totaled US$40.8 million (US$19.5 million cash, US$21.3 million in short-term investments).
Outlook and guidance
Onboarding of U.S. clinical trial sites is expected to allow European sites to resume generating consumable procedure revenue sooner.
Continued regulatory progress and market expansion in Europe, the Middle East, and new geographies such as Australia and New Zealand are key growth drivers.
Impact of trial strategy on revenue and runway?
How will Philips integration accelerate site conversion?
What's the timeline for US market launch readiness?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 032640
Net income surged 61.9% year-over-year, with strong wireless and enterprise growth. - LOT
A$76M equity raise supports Kayelekera ramp-up and Letlhakane development amid strong uranium demand. - SYM
Revenue up 29% to $630M, net income $13.36M, $22.3B backlog, strong cash, legal risks persist. - BPT
H1 FY26 revenue hit AUD 1B, with strong gas prices and LNG cargoes driving results. - CPAY
2026 guidance targets 16% revenue and 22% adjusted EPS growth, led by strong Corporate Payments. - TENB
Record 2025 results with double-digit growth, strong cash flow, and expanding AI-driven platform. - DHX
Q4 2025 revenue down 10% YoY; FY 2026 guidance targets $118M–$122M revenue. - COHR
Q2 FY26 revenue up 17% to $1.69B, with strong EPS growth and robust datacenter demand. - ALGT
Q4 2025 saw record results and margin growth, with 2026 outlook boosted by Sun Country deal. - STC
Record bookings, strong cash flow, and margin expansion drive improved outlook.
Next Imricor Medical Systems earnings date
H2 202525 Feb, 2026
Imricor Medical Systems
Next Imricor Medical Systems earnings date
H2 202525 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Imricor Medical Systems Inc. specializes in the development of innovative MRI-compatible medical devices for MRI-guided cardiac catheter ablation procedures. Their products aim to enhance the success rates and reduce the overall costs of these procedures. Key products from Imricor include the Vision-MR Ablation Catheter and the Advantage-MR EP Recorder/Stimulator, both designed for use under real-time MRI guidance to offer a safer, faster, and more effective treatment compared to traditional x-ray guided catheter ablation methods. Imricor Medical Systems Inc. is headquartered in Burnsville, Minnesota, and its shares are listed on the ASX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage